title: Amine-modified hyaluronic acid-functionalized porous silicon nanoparticles for targeting breast cancer tumors.
abstract: Active targeting of nanoparticles to receptor-overexpressing cancer cells has great potential for enhancing the cellular uptake of nanoparticles and for reducing fast clearance of the nanoparticles from the body. Herein, we present a preparation method of a porous silicon (PSi)-based nanodelivery system for breast cancer targeting, by covalently conjugating a synthesized amide-modified hyaluronic acid (HA(+)) derived polymer on the surface of undecylenic acid-modified thermally hydrocarbonized PSi (UnTHCPSi) nanoparticles. The resulting UnTHCPSi-HA(+) nanoparticles showed relatively small size, reduced polydispersibility, high biocompatibility, improved colloidal and human plasma stability, as well as enhanced cellular interactions and internalization. Moreover, we demonstrated that the enhanced cellular association of UnTHCPSi-HA(+) relies on the capability of the conjugated HA(+) to bind and consequently target CD44 receptors expressed on the surface of breast cancer cells, thus making the HA(+)-functionalized UnTHCPSi nanoparticles a suitable and promising nanoplatform for the targeting of CD44-overexpressing breast tumors and for drug delivery.
authors: Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, FI-00014 University of Helsinki, Finland. helder.santos@helsinki.fi.
authors: Patrick V
authors: PV
authors: Almeida
authors: Mohammad-Ali
authors: MA
authors: Shahbazi
authors: Ermei
authors: E
authors: Mäkilä
authors: Martti
authors: M
authors: Kaasalainen
authors: Jarno
authors: J
authors: Salonen
authors: Jouni
authors: J
authors: Hirvonen
authors: Hélder A
authors: HA
authors: Santos
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry; D001679:Biogenic Amines / Q000737:chemistry / Q000493:pharmacokinetics*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004058:Diffusion; D004339:Drug Compounding / Q000379:methods; D006801:Humans; D006820:Hyaluronic Acid / Q000737:chemistry*; D008422:Materials Testing; D053769:Nanocapsules / Q000008:administration & dosage / Q000737:chemistry*; D058726:Nanoconjugates; D058608:Nanopores / Q000648:ultrastructure; D010316:Particle Size; D016062:Porosity; D012825:Silicon / Q000737:chemistry*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001679:Biogenic Amines; D053769:Nanocapsules; D058726:Nanoconjugates; D006820:Hyaluronic Acid; D012825:Silicon